Tag Archive for: DT001 is a TNF receptor 2 agonistic antibody

Wouter Verhoeven, CEO of Dualyx. © Dualyx NV
financing

Dualyx NV raises €40m in Series A financing

Belgian T reg specialist Dualyx NV had raised €40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic.

Read more